Huang Jiacai nodded, "We shall wait and see."
After returning to Nandu, Huang Jiacai reported the details of the eting to Yang Ping.
"Professor, do you think... he is sincere?" Tang Shun asked.
"At least for now, yes," Huang Jiacai replied, "But sincerity is tested over ti, pressure, and interest changes. He might be sincere personally, but behind him is a vast comrcial empire with a board of directors, shareholders, and a complex network of interests."
"Should we continue to move forward then?" Lu Xiaolu asked.
Huang Jiacai was resolute, "Move forward, but with more caution. The legal clauses must be airtight, the checks and balances must penetrate to the core. This is an opportunity and also a risk. Systemic regulation theory needs to reach a broader world; we need international resources and platforms, but we must ensure our core interests."
While Huang Jiacai was having a secret eting with Li Gaoyang, global public opinion and industry dynamics were experiencing a significant shake-up due to the "defection" of the giants.
The other six major pharmaceutical companies were caught in unprecedented passivity.
Novartis’s Senior Vice President of R&D complained privately to the dia, "We have advocates for systemic dicine internally too, but they were suppressed before. Now, we need to reassess."
Intense debates broke out within Roche’s board; the radicals called for imdiate strategic adjustnts, while the conservatives worried that "inconsistent steps would harm the alliance."
Previously regarded as the "spiritual leader," Professor Horton found himself in the most awkward position. He tried to publish articles to refute Li Gaoyang’s "betrayal," accusing Giant Group of "abandoning scientific rigor for short-term gains," but there were few responses. Instead, more and more scholars, including so of Horton’s forr collaborators, began to publicly support systemic regulation theory.
An analysis article in the "New York Tis" stated, "Li Gaoyang’s declaration was like toppling the first domino. It not only isolated the resistors comrcially but also stripped them of their footing morally and narratively. The road for systemic regulation theory to return to the international mainstream stage, while still with obstacles, has seen the collapse of its greatest conceptual barrier."
anwhile, the patient alliance led by Walker keenly seized this opportunity.
They no longer needed to charge ahead personally. Instead, they began to play the roles of "coordinators" and "supervisors."
Walker had a private phone call with Li Gaoyang. The content was unknown, but afterward, the Giant Group accelerated communication with various national regulatory agencies, and the public pressure from the patient alliance appropriately eased, shifting to "anticipation of concrete results."
This was a subtle tacit understanding: the patient alliance displayed muscle, the Giant Group provided solutions and ladders, and the regulatory agencies, under internal and external pressure, began a substantive transformation as a matter of course.
Two weeks later, the FDA issued a "supplentary statent," clarifying that previous guidelines were "not intended to restrict real systemic dicine research and applications," and announced the formation of an "advanced therapy evaluation task force" composed of multiple stakeholders, with the first eting inviting Yang Ping’s team to make a special report.
The European dicines Agency followed closely, stating it would "re-evaluate" the regulatory classification of systemic regulation therapy, considering the introduction of an "incrental authorization" chanism.
The attitude shift from the Japan Ministry of Health, Labor and Welfare was most dramatic; a previously tough stanced director was relocated, and the new leader publicly stated, "Japan should not fall behind in the dical revolution."
Sanbo Research Institute, team eting.
Tang Shun reported the latest progress, "...Basically, of the sixteen countries on the list, eleven have proactively contacted us, expressing a willingness to renegotiate cooperation, with conditions much more lenient than before. The remaining five are also in intense internal discussions. Horton’s ’Protection Alliance’ has beco nominal. Several major pharmaceutical companies are privately approaching us, eager to explore the specifics of cooperation with the giants, fearing being completely left out."
Lu Xiaolu laughed, "That’s good, now we’ve gone from being besieged to being scrambled for."
"It’s not that simple." Song Zimo shook his head, "Now is the real test for us. Who to choose, how to cooperate, how to balance, how to avoid being exalted to death, the issues are more complex now."
"Let Huang Jiacai handle these things; they are the professionals. We just need to focus on research and start discussing the difficulties encountered in recent experints," Yang Ping said lightly.
User Comments
0 comments from readers